The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis

American Journal of Physiology - Endocrinology and Metabolism

Volumn 271, Issue 5 34-5, 1996, Pages

  Young, Morag J ^a   Funder, John W ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

losartan; mineralocorticoid receptors; perindopril; potassium canrenoate

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANRENOATE POTASSIUM; COLLAGEN; CORTICOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYPROLINE; LOSARTAN; MINERALOCORTICOID RECEPTOR; PERINDOPRIL; SPIRONOLACTONE;

ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MODEL; HEART MUSCLE FIBROSIS; HEART WEIGHT; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029805353     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.1996.271.5.e883     Document Type: Article

References (27)

1. Albiston, A., V. Obeyesekere, R. Smith, and Z. Krozowski. Cloning and tissue distribution of the human 11-β hydroxysteroid dehydrogenase type II enzyme. Mol. Cell. Endocrinol. 105: R11-R17, 1994.
2. Beato, M. Gene regulation by steroid hormones. Cell 56: 335-344, 1989.
3. Brilla, C. G., L. S. Matsubara, and K. T. Weber. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J. Mol. Cell. Cardiol. 25: 563-575, 1993.
4. Brilla, C. G., L. S. Matsubara, and K. T. Weber. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am. J. Cardiol. 71: 12A-16A, 1993.
5. Brilla, C. G., and K. T. Weber. Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J. Lab. Clin. Med. 120: 893-901, 1992.
6. Brilla, C. G., G. Zhou, L. Matsubara, and K. T. Weber. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J. Mol. Cell. Cardiol. 26: 809-820, 1995.
7. Chiarello, M., G. Ambrosio, M. Campelli-Bigazzi, P. Perrone-Filardi, F. Brigante, and C. Sifola. A biochemical method for the quantification of myocardial scarring after experimental coronary artery occlusion. J. Mol. Cell. Cardiol. 18: 283-290, 1986.
8. Cole, T. J. Cloning of the mouse 11β-hydroxysteroid dehydrogenase type 2 gene: tissue specific expression and localization in distal convoluted tubules and collecting ducts of the kidney. Endocrinology 136. 4693-4696, 1995.
9. Edwards, C. R. W., P. M. Stewart, D. Burt, M. A. McIntyre, E. R. de Kloet, L. Brett, W. S. Sutano, and C. Monder. Localization of 11β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 2: 986-989, 1988.
10. Fullerton, M., and J. W. Funder. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc. Res. 28: 1863-1867, 1994.
11. Funder, J. W., P. T. Pearce, R. Smith, and A. I. Smith. Mineralocorticoid action: target-tissue specificity is enzyme, not receptor, mediated. Science Wash. DC 242: 583-585, 1988.
12. Gomez-Sanchez, C. E., M. F. Foecking, M. W. Ferris, M. R. Chavarri, L. Uribe, and E. P. Gomez-Sanchez. The production of monoclonal antibodies against aldosterone. Steroids 49: 581-587, 1989.
13. Gomez-Sanchez, E. P., C. Fort, and D. Thwaites. Central mineralocorticoid receptor antagonism blocks hypertension in Dahl S/JR rats. Am. J. Physiol. 262 (Endocrinol. Metab. 25): E96-E99, 1992.
14. Gomez-Sanchez, E. P., M. T. Venkataraman, D. Thwaites, and C. Fort. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am. J. Physiol. 258 (Endocrinol. Metab. 21): E649-E653, 1990.
15. Kageyama, Y., H. Suzuki, and T. Saruta. Role of glucocorticoid in the development of glycyrrhizin-induced hypertension. Clin. Exp. Hypertens. 16: 761-778, 1994.
16. Ludbrook, J. On making multiple comparisons in clinical and experimental pharmacology and physiology. Clin. Exp. Pharmacol. Physiol. 18: 379-392, 1991.
17. Muller, A. E., L. M. Cruz-Orive, P. Gehr, and E. R. Weibel. Comparison of two subsampling methods for electron microscope morphometry. J. Microsc. Oxf. 123: 35-49, 1981.
18. Myles, K., and J. W. Funder. Type I (mineralocorticoid) receptors in the guinea-pig. Am. J. Physiol. 267 (Endocrinol. Metab. 30): E268-E272, 1994.
19. Myles, K., and J. W. Funder. Progesterone binding to mineralocorticoid receptors: in vitro and in vivo studies. Am. J. Physiol. 270 (Endocrinol. Metab. 33): E601-E607, 1996.
20. Neuss, M., V. Regitz-Zagrosek, A. Hildebrandt, and E. Flech. Human cardiac fibroblasts express an angiotensin receptor with unusual binding characteristics which is coupled to cellular proliferation. Biochem. Biophys. Res. Commun. 204: 1334-1339, 1994.
21. Paul, M., R. Kreutz, M. S. Ferdandez-Alfonso, J. Wagner, D. Ganten, and M. Bohm. Cardiac gene expression of the components of the renin angiotensin system in human cardiomyopathy (Abstract). J. Hypertens. 12, Suppl. 3: S125, 1994.
22. Pearce, P., and J. W. Funder. Steroid binding to cardiac Type I receptors: in vivo studies. J. Hypertens. 6, Suppl. 4: S131-S133, 1988.
23. Slight, S., V. K. Ganjam, and K. T. Weber. Species diversity of 11 β-hydroxysteroid dehydrogenase in the cardiovascular system. J. Lab. Clin. Med. 124: 821-826, 1994.
24. Wehling, M. Aldosterone specific membrane receptors, rapid activation of the sodium hydrogen exchanger, and cardiovascular implications. Cardiovasc. Res. 29: 167-171, 1995.
25. Young, M. J., M. Fullerton, R. Dilley, and J. W. Funder. Mineralocorticoids, hypertension and cardiac fibrosis. J. Clin. Invest. 93. 2578-2583, 1994.
26. Young, M. J., G. Head, and J. W. Funder. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am. J. Physiol. 269 (Endocrinol. Metab. 32): E657-E662, 1995
27. Yu, H., H. Rakugi, F. Nakamura, J. Higaki, H. Mikami, and T. Ogihara. The role of augmented tissue angiotensin formation in cardiovascular hypertrophy in IK1C hypertension (Abstract) J. Hypertens. 12, Suppl. 3: S215, 1994.